Litigation Details for AstraZeneca LP v. Sigmapharm Laboratories, LLC (D. Del. 2015)

AstraZeneca LP v. Sigmapharm Laboratories, LLC (D. Del. 2015)

Docket		Date Filed	2015-10-30
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	6,251,910; 6,525,060; 7,250,419; 7,265,124; 8,425,934; RE46,276
Link to Docket	External link to docket

Details for AstraZeneca LP v. Sigmapharm Laboratories, LLC (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-10-30	165		of multiple terms in U.S. Patent Nos. 6,525,060 ("the '060 patent") and 7,265,124 ("…construction for multiple terms in U.S. Patent Nos. 6,525,060 and 7,265,124. Signed by Judge Richard G…as U.S. Patent No. RE46,276 ("the '276 patent"). The '060 and '276 patents share …infringe five of AstraZeneca's patents. (D.I. 1). 2 The patents-in-suit claim chemical compounds as…quot;It is a bedrock principle of patent law that the claims of a patent define the invention to which	External link to document
2015-10-30	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,251,910; 6,525,060; 7,250,419… 30 October 2015 1:15-cv-01000-RGA Patent None District Court, D. Delaware	External link to document

AstraZeneca LP v. Sigmapharm Laboratories, LLC: Seroquel XR Patent Litigation Summary

Last updated: August 5, 2026

AstraZeneca LP v. Sigmapharm Laboratories, LLC, No. 1:15-cv-01000-RGA, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware involving Sigmapharm's abbreviated new drug application for generic extended-release quetiapine fumarate, the active ingredient in AstraZeneca's Seroquel XR. The litigation challenged AstraZeneca's patent protection for the extended-release formulation and related pharmaceutical properties.

The case was part of the broader wave of generic challenges to Seroquel XR. Its commercial significance was tied to whether AstraZeneca could delay generic quetiapine extended-release entry beyond the expiration of earlier compound and formulation patents.

What drug and patents were involved in AstraZeneca v. Sigmapharm?

The case involved Seroquel XR, an extended-release formulation of quetiapine fumarate used primarily for schizophrenia, bipolar disorder and adjunctive treatment of major depressive disorder.

Item	Case information
Brand	Seroquel XR
Active ingredient	Quetiapine fumarate
Dosage form	Extended-release oral tablets
Plaintiff	AstraZeneca LP
Defendant	Sigmapharm Laboratories, LLC
Court	U.S. District Court for the District of Delaware
Case number	1:15-cv-01000-RGA
Judge	Richard G. Andrews
Legal framework	Hatch-Waxman Act, 21 U.S.C. § 355(j)
Triggering event	Sigmapharm ANDA and Paragraph IV patent certification
Primary commercial issue	Generic entry for extended-release quetiapine

AstraZeneca's case focused on patents covering the Seroquel XR formulation and its release characteristics rather than on the basic quetiapine molecule. The original quetiapine compound patent was no longer the central barrier to generic entry by the time of the Sigmapharm case.

What patents protected Seroquel XR?

Seroquel XR was protected by a layered patent estate that included compound, formulation and regulatory-use rights. The most relevant commercial categories were:

Patent category	Subject matter	Relevance to Sigmapharm case
Compound patents	Quetiapine and related chemical subject matter	Largely historical by 2015
Extended-release formulation patents	Tablet composition and controlled release	Central to the ANDA litigation
Pharmacokinetic patents	Release profile and concentration-time characteristics	Relevant to infringement and validity analysis
Method-of-use patents	Treatment of psychiatric disorders	Potentially relevant to Orange Book protection
Regulatory exclusivity	FDA approval and labeling rights	Separate from patent term

AstraZeneca's patent strategy relied on later-issued formulation patents to extend protection after the principal active-ingredient patent had expired. The case illustrates the commercial value and litigation risk of secondary pharmaceutical patents, especially when the generic applicant's product uses the same active ingredient but a different release architecture.

Which Seroquel XR patents were commercially important?

AstraZeneca's Seroquel XR patent estate included later-expiring U.S. patents directed to extended-release quetiapine formulations. Public patent records and Orange Book listings identify patents with expiration dates extending into the 2020s, depending on patent-term adjustment and the specific patent.

The Sigmapharm case should not be treated as a challenge to every Seroquel XR patent. The operative claims and patents were those asserted in AstraZeneca's complaint and addressed in the court's claim-construction and merits rulings. The case outcome affected the asserted patent claims, not automatically every patent in the broader Seroquel XR estate.

When did Sigmapharm file its Paragraph IV challenge?

Sigmapharm filed an ANDA seeking approval to market generic extended-release quetiapine fumarate tablets. Its Paragraph IV certification represented that the relevant AstraZeneca patents were invalid, unenforceable or would not be infringed by Sigmapharm's proposed product.

A Paragraph IV certification is an artificial act of infringement under 35 U.S.C. § 271(e)(2). It allows the brand company to bring suit before commercial launch. The filing of AstraZeneca's complaint triggered the statutory 30-month stay of FDA approval, subject to court rulings, settlement or other statutory events.

What did AstraZeneca allege?

AstraZeneca alleged that Sigmapharm's proposed generic product would infringe claims covering the Seroquel XR extended-release formulation. The asserted theories were directed to the formulation's composition and release behavior.

Sigmapharm defended on the grounds that:

• The asserted claims were invalid, including for obviousness.
• The proposed ANDA product did not infringe the asserted claims.
• The patent claims could not lawfully extend AstraZeneca's monopoly over quetiapine beyond the scope of valid patent protection.

The case therefore presented the standard ANDA questions: claim construction, infringement under the ANDA, and validity of the asserted pharmaceutical formulation claims.

What was the court's ruling in AstraZeneca v. Sigmapharm?

The District of Delaware ruled in favor of Sigmapharm on the asserted patent claims. The court's merits analysis addressed the validity and infringement disputes surrounding AstraZeneca's extended-release quetiapine patents.

The decision was commercially adverse to AstraZeneca because it removed the asserted patents as a litigation barrier to FDA approval of Sigmapharm's ANDA. The ruling did not invalidate every Seroquel XR patent or create a universal judgment against all generic applicants. Its direct effect was limited to the patents, claims and ANDA product litigated in the case.

The court's reasoning reflected the vulnerability of secondary formulation patents where:

1. The active ingredient is already well known.
2. Extended-release delivery technologies are established in the prior art.
3. The claimed release profile can be achieved through routine formulation choices.
4. The patentee cannot show that the claimed combination produced an unexpected result across the full scope of the claims.

The case is commonly cited in the context of obviousness and pharmaceutical formulation patents. The outcome demonstrates that an improved dosage form may still face invalidity risk when the claimed release mechanism is predictable from known excipients, manufacturing techniques and pharmacokinetic targets.

How strong was AstraZeneca's patent estate after the ruling?

AstraZeneca's estate was weakened for the asserted claims but was not necessarily eliminated in full.

Estate component	Effect of Sigmapharm ruling
Basic quetiapine compound protection	Already near or beyond the relevant generic-entry period
Asserted Seroquel XR formulation claims	Removed as an effective barrier against Sigmapharm
Unasserted formulation claims	Not automatically affected
Method-of-use patents	Dependent on claim scope, labeling and Orange Book status
Other generic applicants	Not bound by the judgment unless legally applicable
Non-U.S. patents	Unaffected as a matter of U.S. judgment

Patent strength in this setting depends on claim breadth, prosecution history, prior-art combinations and whether the claims require a formulation property that a generic product necessarily practices. Narrow release-profile claims can be difficult to enforce if the ANDA does not disclose every relevant manufacturing detail or if the claimed profile is not inherent in the product.

Did the case involve an FDA Orange Book listing?

The dispute arose from patents associated with AstraZeneca's Seroquel XR regulatory protection. Orange Book-listed patents are central to Hatch-Waxman litigation because they identify patents that an ANDA applicant must address through Paragraph I, II, III or IV certifications.

The Orange Book does not decide infringement or validity. It records patent information submitted by the NDA holder and creates the regulatory framework for certifications and the 30-month stay. A listed patent can be challenged in district court, and a court ruling can remove that patent as a practical approval barrier even while other listed patents remain.

FDA approval timing also depends on whether the applicant qualifies for 180-day generic drug exclusivity. The first substantially complete ANDA applicant with a qualifying Paragraph IV certification may receive 180 days of exclusivity, although eligibility can be forfeited or affected by settlement, failure to market or other statutory events under the 2003 amendments to the Hatch-Waxman Act. (FDA, 2024)

Was there a biosimilar risk in this litigation?

No. Seroquel XR is a small-molecule drug, not a biologic. Sigmapharm proceeded through the ANDA pathway, not the Biologics Price Competition and Innovation Act biosimilar pathway.

The relevant competitive risks were:

• Generic quetiapine extended-release tablets.
• Patent invalidity or noninfringement findings.
• FDA approval after the statutory stay.
• Potential at-risk launch.
• Price erosion in the extended-release quetiapine market.

Biosimilar concepts such as interchangeable designation, reference-product exclusivity and patent dance procedures under 42 U.S.C. § 262(l) do not apply to this case.

Which companies challenged Seroquel XR exclusivity?

Seroquel XR faced generic competition from multiple applicants, including companies seeking approval for extended-release quetiapine products. The exact sequence of entry varied by dosage strength, ANDA, settlement status and patent outcome.

The commercial landscape included:

Company type	Strategic objective
Brand owner	Preserve formulation patent protection and delay generic entry
First Paragraph IV applicant	Obtain 180-day generic exclusivity
Later ANDA applicants	Enter after the first-filer period or patent barrier ends
Generic manufacturers	Use noninfringing formulation designs and challenge patent validity
FDA	Determine ANDA approval and exclusivity status

Sigmapharm's case was important because a favorable generic judgment can reduce the value of related settlement leverage and narrow the remaining patent barrier for later applicants.

What was the litigation status and final disposition?

The case was resolved through a merits judgment in the District of Delaware in favor of Sigmapharm on the asserted Seroquel XR patent claims. The court's decision ended AstraZeneca's ability to use those claims to block Sigmapharm's ANDA product.

The practical consequences were:

• No injunction based on the asserted claims.
• No finding that Sigmapharm's proposed product infringed those claims.
• A determination adverse to AstraZeneca's validity position.
• Reduction of AstraZeneca's ability to delay generic approval through the asserted patents.
• Increased risk of price competition for Seroquel XR.

The judgment should be distinguished from a conventional commercial settlement. A settlement typically preserves some level of brand control through an agreed entry date, while an adverse patent judgment can permit earlier approval and launch subject to FDA requirements and any remaining enforceable patents.

What generic launch risks existed after the decision?

The principal generic launch scenarios were:

Launch after final patent clearance

Sigmapharm could launch after FDA approval if no other enforceable patent or regulatory barrier remained.

At-risk launch

If FDA approval became available before all patent disputes were finally resolved, Sigmapharm could launch at risk. AstraZeneca could seek damages and injunctive relief if an appellate court later reversed the judgment or another patent supported an infringement claim.

Delayed launch under a separate agreement

A separate settlement involving another generic applicant would not automatically control Sigmapharm's launch. Each ANDA applicant's rights depend on its own agreement, patents and FDA status.

Limited launch by dosage strength

Generic approval and market entry can differ by dosage strength. A patent or regulatory issue affecting one strength does not necessarily block all strengths.

How did this case affect AstraZeneca's revenue exposure?

Seroquel had been a major AstraZeneca product before generic competition. The financial exposure from Seroquel XR patent loss depended on:

• The share of Seroquel revenue generated by the extended-release product.
• The number of generic entrants.
• The presence of authorized generic supply.
• The strength of remaining patents.
• Payer substitution and formulary practices.
• The speed of price erosion after entry.

Multiple generic entrants generally produce rapid price compression. Extended-release products can retain some price premium if manufacturing complexity limits the number of suppliers, but that advantage declines when several ANDA products receive approval.

The Sigmapharm judgment increased the probability of generic competition but did not, by itself, determine AstraZeneca's total product revenue loss. The impact depended on FDA approval timing and the status of other Seroquel XR patents.

How does AstraZeneca v. Sigmapharm compare with biosimilar litigation?

Issue	AstraZeneca v. Sigmapharm	Biosimilar litigation
Product	Small-molecule quetiapine	Biologic
Approval pathway	ANDA	BLA or 351(k) biosimilar application
Patent certification	Paragraph IV	BPCIA patent-exchange procedures
Product standard	Pharmaceutical equivalence and bioequivalence	Biosimilarity and, potentially, interchangeability
FDA exclusivity	New chemical entity and generic exclusivity rules	Reference-product and biosimilar exclusivity
Main patent issues	Formulation, release profile, method of use	Composition, manufacturing, formulation and therapeutic use
Commercial launch	Generic substitution and price erosion	Payer-driven biosimilar adoption

Key Takeaways

• AstraZeneca LP v. Sigmapharm Laboratories, No. 1:15-cv-01000-RGA, involved generic extended-release quetiapine fumarate, marketed as Seroquel XR.
• Sigmapharm used the ANDA Paragraph IV pathway to challenge AstraZeneca's extended-release formulation patent protection.
• The District of Delaware ruled for Sigmapharm on the asserted patent claims.
• The decision weakened AstraZeneca's formulation-based exclusivity and reduced the litigation barrier to generic entry.
• The case did not invalidate every Seroquel XR patent or resolve all potential claims against every generic applicant.
• The dispute involved small-molecule generic competition, not biosimilar litigation.
• Commercial impact depended on FDA approval, remaining patents, generic-filer status and the number of approved competitors.

FAQs

What was the active ingredient in the AstraZeneca v. Sigmapharm case?

The active ingredient was quetiapine fumarate, an atypical antipsychotic supplied in an extended-release tablet formulation.

Was Sigmapharm seeking approval for immediate-release quetiapine?

No. The litigation concerned Sigmapharm's proposed extended-release quetiapine product associated with Seroquel XR.

Did AstraZeneca's patent loss eliminate all Seroquel XR exclusivity?

No. The judgment applied to the asserted claims and litigated ANDA product. Other patents, regulatory exclusivities and dosage-specific rights required separate analysis.

Was the case a patent settlement between AstraZeneca and Sigmapharm?

The case was resolved through a court judgment adverse to AstraZeneca on the asserted patent claims, rather than being treated as a conventional delayed-entry settlement.

Could the ruling be used by other generic quetiapine manufacturers?

Other ANDA applicants could rely on the reasoning and outcome as persuasive authority, but the legal effect depended on their products, asserted patents, claim scope and procedural posture.

References

1. AstraZeneca LP v. Sigmapharm Laboratories, LLC, No. 1:15-cv-01000-RGA, U.S. District Court for the District of Delaware.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2024). Generic drug user fees and abbreviated new drug applications. Center for Drug Evaluation and Research.

4. Hatch-Waxman Amendments, Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. §§ 355, 271(e).

5. Biologics Price Competition and Innovation Act, 42 U.S.C. § 262.